Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Wegovy for Weight Loss in Obesity
NCT06633783Phase 3Not yet recruiting
- Sponsor
- Jiuyuan Gene Engineering
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Jiuyuan Gene Engineering. Primary endpoint: Change in body weight at 44 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06633783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633783.